For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Icosapent - Lipid modification
PAD Profile : Icosapent - Lipid modification
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Atorvastatin
- Rosuvastatin calcium
- Simvastatin
- Ezetimibe
- Pravastatin sodium
- Fluvastatin sodium
- Evolocumab
- Alirocumab
- Fenofibrate
- Bezafibrate
- Ciprofibrate
- Gemfibrozil
- Colesevelam hydrochloride
- Colestyramine
- Bempedoic acid
- Inclisiran
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve Icosapent ethyl with statin therapy as a treatment option for reducing the risk of cardiovascular events in people with raised triglycerides in line with NICE TA805.
Icosapent ethyl for this indication will be considered as GREEN on the traffic light status.
The committee noted an increased risk of atrial fibrillation or fluttter - prescribers should consider advice given in the Summary of Product Charcteristics available at https://www.medicines.org.uk/emc/product/12964